*** For details on how to be removed from this list visit the ***
*** CCP4 home page http://www.ccp4.ac.uk ***
The eCheminfo Community of Practice InterAction Meeting
"Latest Advances in Drug Discovery Design & Planning
Methods" will take place 16-19 October 2006, Bryn Mawr,
Philadelphia, USA
Program themes include Structure-based Drug Design,
Screening & Docking, Cheminformatics & Modeling supporting
Medicinal Chemistry, Pharmacophores, Metabolomics, Quantum
Biochemistry, Knowledge Management, Electronic Lab
Notebooks, Critical Path Innovation in Drug Development,
Biomarkers, Predictive Toxicology & ADME. In addition to
morning presentations and panel discussions, workshops
will run each afternoon expanding on the discussion of
topics and methods and working through the application of
new methods and software to drug discovery & development
problems, with bbq, social activity and poster sessions
running on campus during the evenings.
The preliminary program and schedule is available at:
http://www.echeminfo.com/COMTY_conferences/
Reduced rates apply for early registration through 30
June. Academic discounts apply.
All registrants are eligible to submit an abstract (ca.
300 words) for the poster sessions.
Please address any questions related to the conference,
exhibition or workshop program to me. Registration
enquiries should be directed to eCheminfo [at]
douglasconnect.com
best regards
Barry Hardy
eCheminfo Community of Practice
Douglas Connect
Baermeggenweg 14, Zeiningen
CH-4314, Switzerland
Tel: +41 61 851 0170
Confirmed Speakers at the Bryn Mawr meeting include:
Frank Hollinger (Locus Pharmaceuticals), Erin Duffy
(Rib-X), Mike Malams (Wyeth), Debananda Das (NCI), Max
Cummings (Johnson & Johnson PR&D), Lance Westerhoff
(QuantumBio), Jose Duca (Schering-Plough), Osman Guner
(Turquoise Consulting), Hege Beard (Schrodinger), Stan
Young (NISS), John Irwin (UCSF), William Douglas Figg
(NCI), Daryll Reid (Simbiosys), Gregory Warren
(GlaxoSmithKline), Deepak Bandyopadhyay (Johnson & Johnson
PR&D), Paul Hawkins (OpenEye), Chris Cooper (BMS), James
Arnold (Astra-Zeneca), Phil Edwards (Astra-Zeneca), Pete
Connolly (Johnson & Johnson PR&D), Dimitris Agrafiotis
(Johnson & Johnson PRD), Jim Wikel (Coalesix), Tudor Oprea
(Univ. New Mexico), Alex Tropsha (UNC), Curt Breneman
(RPI), Sanji Bhal (ACD/Labs), Michael Bolger (Simulations
Plus), Bob Clark (Tripos), Gilles Klopman (Multicase),
Navita Mallalieu (Roche Pharmaceuticals), Deepak
Bandyopadhyay (Johnson & Johnson PR&D), Zentam Tsuchihashi
(BMS), Peter Henstock (Pfizer), Darius Dziuda
(Multivariate bioMarkers Discovery), Keith Elliston
(Genstruct), Michael Liebman (Windber Research Institute),
Jonathan Sheldon (InforSense), Duane Shugars (Concentia
Digital), Jian Wang (Biofortis), Peter Gates (Johnson &
Johnson PR&D), Barry Hardy (Douglas Connect), Dennis
Underwood (Praxeon), Jeff Spitzner (Rescentris), David
Mosenkis (Spotfire), Joel Hoffman (IntraSphere), Delia
Wolf (Harvard Medical School), Craig Liddell (Realtime
Science), Joseph Bitran (Enterprizer), Alvin Berger
(Metabolon), Gregory Banik (Bio-RAD), George Harrigan
(Monsanto), Rick Beger (NCTR, FDA), Don Robertson
(Pfizer), Teresa Garret (Duke University), Laszlo Boros
(SIDMAP), Bruce Kristal (Cornell University), Andrew Lane
(JG Brown Cancer Center, U. Louisville), Oliver Fiehn (UC
Davis Genome Center), Susan Connor (Glaxo SmithKline)
